Skip to main content
  • Register
  • Help
  • Contact us

Aldeyra Therapeutics Inc (ALDX) USD0.001

Sell:$12.34 Buy:$12.37 Change: $0.30 (2.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$12.34
Buy:$12.37
Change: $0.30 (2.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$12.34
Buy:$12.37
Change: $0.30 (2.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Contact details

Address:
131 Hartwell Ave Ste 320
LEXINGTON
02421-3105
United States
Telephone:
+1 (781) 7614904
Website:
https://www.aldeyra.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALDX
ISIN:
US01438T1060
Market cap:
$584.38 million
Shares in issue:
48.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Douglas
    Independent Chairman of the Board
  • Todd Brady
    President, Chief Executive Officer, Director
  • Joshua Reed
    Chief Financial Officer
  • James Gow
    Senior Vice President - Clinical Development
  • Stephen Machatha
    Senior Vice President, Technical Operations
  • David McMullin
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.